Main variables;Fields of operation;Total
Companies that perform R+D in Biotechnology;Total 2021;1.547
Companies that perform R+D in Biotechnology;Companies;1.348
Companies that perform R+D in Biotechnology;P.A.;120
Companies that perform R+D in Biotechnology;Higher Education;66
Companies that perform R+D in Biotechnology;PNPI;13
%Companies according to biotechnology used: Genetic code;Total 2021;38
%Companies according to biotechnology used: Genetic code;Companies;31
%Companies according to biotechnology used: Genetic code;P.A.;87,5
%Companies according to biotechnology used: Genetic code;Higher Education;89,4
%Companies according to biotechnology used: Genetic code;PNPI;46,2
%Companies according to biotechnology used: Functional Companies;Total 2021;44,8
%Companies according to biotechnology used: Functional Companies;Companies;38,4
%Companies according to biotechnology used: Functional Companies;P.A.;88,3
%Companies according to biotechnology used: Functional Companies;Higher Education;93,9
%Companies according to biotechnology used: Functional Companies;PNPI;53,8
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total 2021;28,8
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Companies;21,7
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;P.A.;73,3
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Higher Education;86,4
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;PNPI;61,5
%Companies according to biotechnology used: Bioprocesses;Total 2021;53
%Companies according to biotechnology used: Bioprocesses;Companies;50,3
%Companies according to biotechnology used: Bioprocesses;P.A.;58,3
%Companies according to biotechnology used: Bioprocesses;Higher Education;93,9
%Companies according to biotechnology used: Bioprocesses;PNPI;69,2
%Companies according to biotechnology used: Sub-cellular organisms;Total 2021;14,8
%Companies according to biotechnology used: Sub-cellular organisms;Companies;8,2
%Companies according to biotechnology used: Sub-cellular organisms;P.A.;53,3
%Companies according to biotechnology used: Sub-cellular organisms;Higher Education;74,2
%Companies according to biotechnology used: Sub-cellular organisms;PNPI;38,5
%Companies according to biotechnology used: Bio-computing;Total 2021;30,7
%Companies according to biotechnology used: Bio-computing;Companies;24,1
%Companies according to biotechnology used: Bio-computing;P.A.;73,3
%Companies according to biotechnology used: Bio-computing;Higher Education;87,9
%Companies according to biotechnology used: Bio-computing;PNPI;30,8
%Companies according to biotechnology used: Nanobiotechnology;Total 2021;17,7
%Companies according to biotechnology used: Nanobiotechnology;Companies;11,8
%Companies according to biotechnology used: Nanobiotechnology;P.A.;54,2
%Companies according to biotechnology used: Nanobiotechnology;Higher Education;72,7
%Companies according to biotechnology used: Nanobiotechnology;PNPI;15,4
%Companies according to biotechnology used: Other;Total 2021;14,9
%Companies according to biotechnology used: Other;Companies;16,4
%Companies according to biotechnology used: Other;P.A.;3,3
%Companies according to biotechnology used: Other;Higher Education;7,6
%Companies according to biotechnology used: Other;PNPI;0
Companies in which biotechnology activities are:  Main and/or exclusive;Total 2021;705
Companies in which biotechnology activities are:  Main and/or exclusive;Companies;661
Companies in which biotechnology activities are:  Main and/or exclusive;P.A.;31
Companies in which biotechnology activities are:  Main and/or exclusive;Higher Education;3
Companies in which biotechnology activities are:  Main and/or exclusive;PNPI;10
Companies in which biotechnology activities are: A secondary line of business;Total 2021;276
Companies in which biotechnology activities are: A secondary line of business;Companies;188
Companies in which biotechnology activities are: A secondary line of business;P.A.;41
Companies in which biotechnology activities are: A secondary line of business;Higher Education;46
Companies in which biotechnology activities are: A secondary line of business;PNPI;1
Companies in which biotechnology activities are: A tool necessary for production;Total 2021;567
Companies in which biotechnology activities are: A tool necessary for production;Companies;500
Companies in which biotechnology activities are: A tool necessary for production;P.A.;48
Companies in which biotechnology activities are: A tool necessary for production;Higher Education;17
Companies in which biotechnology activities are: A tool necessary for production;PNPI;2
%Companies by field(s) of ultimate application of biotechnology use: Human Health;Total 2021;50,5
%Companies by field(s) of ultimate application of biotechnology use: Human Health;Companies;45,8
%Companies by field(s) of ultimate application of biotechnology use: Human Health;P.A.;76,7
%Companies by field(s) of ultimate application of biotechnology use: Human Health;Higher Education;95,5
%Companies by field(s) of ultimate application of biotechnology use: Human Health;PNPI;69,2
%Companies by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total 2021;17,8
%Companies by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Companies;15,3
%Companies by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;P.A.;17,5
%Companies by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Higher Education;69,7
%Companies by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;PNPI;23,1
%Companies by field(s) of ultimate application of biotechnology use: Food products;Total 2021;32,9
%Companies by field(s) of ultimate application of biotechnology use: Food products;Companies;31,5
%Companies by field(s) of ultimate application of biotechnology use: Food products;P.A.;24,2
%Companies by field(s) of ultimate application of biotechnology use: Food products;Higher Education;81,8
%Companies by field(s) of ultimate application of biotechnology use: Food products;PNPI;7,7
%Companies by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total 2021;25,7
%Companies by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Companies;23,7
%Companies by field(s) of ultimate application of biotechnology use: Agriculture and forest production;P.A.;22,5
%Companies by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Higher Education;72,7
%Companies by field(s) of ultimate application of biotechnology use: Agriculture and forest production;PNPI;23,1
%Companies by field(s) of ultimate application of biotechnology use: Environment;Total 2021;19
%Companies by field(s) of ultimate application of biotechnology use: Environment;Companies;15,5
%Companies by field(s) of ultimate application of biotechnology use: Environment;P.A.;25,8
%Companies by field(s) of ultimate application of biotechnology use: Environment;Higher Education;78,8
%Companies by field(s) of ultimate application of biotechnology use: Environment;PNPI;7,7
%Companies by field(s) of ultimate application of biotechnology use: Industry;Total 2021;15,8
%Companies by field(s) of ultimate application of biotechnology use: Industry;Companies;13,4
%Companies by field(s) of ultimate application of biotechnology use: Industry;P.A.;14,2
%Companies by field(s) of ultimate application of biotechnology use: Industry;Higher Education;68,2
%Companies by field(s) of ultimate application of biotechnology use: Industry;PNPI;7,7
Personnel in R&D in biotechnology (no. of persons);Total 2021;47.144
Personnel in R&D in biotechnology (no. of persons);Companies;15.744
Personnel in R&D in biotechnology (no. of persons);P.A.;15.418
Personnel in R&D in biotechnology (no. of persons);Higher Education;15.757
Personnel in R&D in biotechnology (no. of persons);PNPI;225
Personnel in R&D in biotechnology (no. of persons): Research personnel;Total 2021;30.818
Personnel in R&D in biotechnology (no. of persons): Research personnel;Companies;8.380
Personnel in R&D in biotechnology (no. of persons): Research personnel;P.A.;9.510
Personnel in R&D in biotechnology (no. of persons): Research personnel;Higher Education;12.778
Personnel in R&D in biotechnology (no. of persons): Research personnel;PNPI;150
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Total 2021;16.326
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Companies;7.364
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;P.A.;5.908
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Higher Education;2.979
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;PNPI;75
Personnel in R&D in biotechnology (no. of persons). Women;Total 2021;26.646
Personnel in R&D in biotechnology (no. of persons). Women;Companies;8.725
Personnel in R&D in biotechnology (no. of persons). Women;P.A.;9.684
Personnel in R&D in biotechnology (no. of persons). Women;Higher Education;8.101
Personnel in R&D in biotechnology (no. of persons). Women;PNPI;136
Personnel in R&D in biotechnology (no. of persons). Women. Research personnel;Total 2021;16.551
Personnel in R&D in biotechnology (no. of persons). Women. Research personnel;Companies;4.521
Personnel in R&D in biotechnology (no. of persons). Women. Research personnel;P.A.;5.637
Personnel in R&D in biotechnology (no. of persons). Women. Research personnel;Higher Education;6.314
Personnel in R&D in biotechnology (no. of persons). Women. Research personnel;PNPI;79
Personnel in R&D in biotechnology (no. of persons). Women. Technical and auxiliary personnel;Total 2021;10.095
Personnel in R&D in biotechnology (no. of persons). Women. Technical and auxiliary personnel;Companies;4.204
Personnel in R&D in biotechnology (no. of persons). Women. Technical and auxiliary personnel;P.A.;4.047
Personnel in R&D in biotechnology (no. of persons). Women. Technical and auxiliary personnel;Higher Education;1.787
Personnel in R&D in biotechnology (no. of persons). Women. Technical and auxiliary personnel;PNPI;57
Personnel in R&D in biotechnology (FTE);Total 2021;32.896,3
Personnel in R&D in biotechnology (FTE);Companies;11.523,2
Personnel in R&D in biotechnology (FTE);P.A.;11.271,7
Personnel in R&D in biotechnology (FTE);Higher Education;9.934,5
Personnel in R&D in biotechnology (FTE);PNPI;166,9
Personnel in R&D in biotechnology (FTE): Research personnel;Total 2021;20.944,7
Personnel in R&D in biotechnology (FTE): Research personnel;Companies;6.341,6
Personnel in R&D in biotechnology (FTE): Research personnel;P.A.;6.454,3
Personnel in R&D in biotechnology (FTE): Research personnel;Higher Education;8.036
Personnel in R&D in biotechnology (FTE): Research personnel;PNPI;112,8
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Total 2021;11.951,6
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Companies;5.181,6
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;P.A.;4.817,4
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Higher Education;1.898,5
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;PNPI;54,1
Personnel in R&D in biotechnology (FTE). Women;Total 2021;18.965,5
Personnel in R&D in biotechnology (FTE). Women;Companies;6.552,7
Personnel in R&D in biotechnology (FTE). Women;P.A.;7.077,3
Personnel in R&D in biotechnology (FTE). Women;Higher Education;5.228
Personnel in R&D in biotechnology (FTE). Women;PNPI;107,5
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Total 2021;11.346
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Companies;3.464,4
Personnel in R&D in biotechnology (FTE). Women: Research personnel;P.A.;3.786,8
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Higher Education;4.032,9
Personnel in R&D in biotechnology (FTE). Women: Research personnel;PNPI;61,9
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Total 2021;7.619,5
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Companies;3.088,3
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;P.A.;3.290,5
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Higher Education;1.195,1
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;PNPI;45,6
Internal expenditure on R&D (thousands of euros);Total 2021;2.269.251
Internal expenditure on R&D (thousands of euros);Companies;1.037.887
Internal expenditure on R&D (thousands of euros);P.A.;716.877
Internal expenditure on R&D (thousands of euros);Higher Education;500.703
Internal expenditure on R&D (thousands of euros);PNPI;13.783
1) By nature of the expense: Current expenses;Total 2021;2.086.468
1) By nature of the expense: Current expenses;Companies;939.471
1) By nature of the expense: Current expenses;P.A.;672.607
1) By nature of the expense: Current expenses;Higher Education;461.216
1) By nature of the expense: Current expenses;PNPI;13.174
1.1) Remuneration to research personnel;Total 2021;872.151
1.1) Remuneration to research personnel;Companies;321.525
1.1) Remuneration to research personnel;P.A.;252.863
1.1) Remuneration to research personnel;Higher Education;293.131
1.1) Remuneration to research personnel;PNPI;4.630
1.2) Remuneration to technicians and auxiliary personnel;Total 2021;384.242
1.2) Remuneration to technicians and auxiliary personnel;Companies;194.656
1.2) Remuneration to technicians and auxiliary personnel;P.A.;128.640
1.2) Remuneration to technicians and auxiliary personnel;Higher Education;59.408
1.2) Remuneration to technicians and auxiliary personnel;PNPI;1.538
1.3) Other current expenses;Total 2021;830.076
1.3) Other current expenses;Companies;423.290
1.3) Other current expenses;P.A.;291.103
1.3) Other current expenses;Higher Education;108.677
1.3) Other current expenses;PNPI;7.006
2) By nature of the expense: Capital expenses;Total 2021;182.782
2) By nature of the expense: Capital expenses;Companies;98.416
2) By nature of the expense: Capital expenses;P.A.;44.270
2) By nature of the expense: Capital expenses;Higher Education;39.487
2) By nature of the expense: Capital expenses;PNPI;610
2.1) Land and buildings;Total 2021;20.257
2.1) Land and buildings;Companies;10.150
2.1) Land and buildings;P.A.;2.712
2.1) Land and buildings;Higher Education;7.373
2.1) Land and buildings;PNPI;23
2.2) Equipment and instruments;Total 2021;144.096
2.2) Equipment and instruments;Companies;72.538
2.2) Equipment and instruments;P.A.;40.235
2.2) Equipment and instruments;Higher Education;30.775
2.2) Equipment and instruments;PNPI;549
2.3) Acquisition of specific R+D software;Total 2021;8.151
2.3) Acquisition of specific R+D software;Companies;5.713
2.3) Acquisition of specific R+D software;P.A.;1.102
2.3) Acquisition of specific R+D software;Higher Education;1.303
2.3) Acquisition of specific R+D software;PNPI;33
2.4) Otros productos de propiedad intelectual específicos para I+D;Total 2021;10.278
2.4) Otros productos de propiedad intelectual específicos para I+D;Companies;10.015
2.4) Otros productos de propiedad intelectual específicos para I+D;P.A.;222
2.4) Otros productos de propiedad intelectual específicos para I+D;Higher Education;36
2.4) Otros productos de propiedad intelectual específicos para I+D;PNPI;5
1.1) By origin of the funds: Own funds;Total 2021;891.115
1.1) By origin of the funds: Own funds;Companies;711.037
1.1) By origin of the funds: Own funds;P.A.;88.338
1.1) By origin of the funds: Own funds;Higher Education;88.167
1.1) By origin of the funds: Own funds;PNPI;3.574
1.2) By origin of the funds: From companies;Total 2021;247.985
1.2) By origin of the funds: From companies;Companies;121.595
1.2) By origin of the funds: From companies;P.A.;97.993
1.2) By origin of the funds: From companies;Higher Education;25.096
1.2) By origin of the funds: From companies;PNPI;3.301
1.3) By origin of the funds: Public Administration funds;Total 2021;882.530
1.3) By origin of the funds: Public Administration funds;Companies;107.422
1.3) By origin of the funds: Public Administration funds;P.A.;430.689
1.3) By origin of the funds: Public Administration funds;Higher Education;342.018
1.3) By origin of the funds: Public Administration funds;PNPI;2.402
1.4) By origin of the funds: From Universities;Total 2021;3.851
1.4) By origin of the funds: From Universities;Companies;192
1.4) By origin of the funds: From Universities;P.A.;1.388
1.4) By origin of the funds: From Universities;Higher Education;2.220
1.4) By origin of the funds: From Universities;PNPI;50
1.5) By origin of the funds: From non profit private institutions;Total 2021;47.810
1.5) By origin of the funds: From non profit private institutions;Companies;10.756
1.5) By origin of the funds: From non profit private institutions;P.A.;26.599
1.5) By origin of the funds: From non profit private institutions;Higher Education;7.719
1.5) By origin of the funds: From non profit private institutions;PNPI;2.737
1.6) By origin of the funds: Foreign funds;Total 2021;195.959
1.6) By origin of the funds: Foreign funds;Companies;86.884
1.6) By origin of the funds: Foreign funds;P.A.;71.871
1.6) By origin of the funds: Foreign funds;Higher Education;35.483
1.6) By origin of the funds: Foreign funds;PNPI;1.720
Purchase of services R & D in Biotechnology to (thousands of euros);Total 2021;174.817
Purchase of services R & D in Biotechnology to (thousands of euros);Companies;145.440
Purchase of services R & D in Biotechnology to (thousands of euros);P.A.;23.461
Purchase of services R & D in Biotechnology to (thousands of euros);Higher Education;3.058
Purchase of services R & D in Biotechnology to (thousands of euros);PNPI;2.858
Purchase of services R & D in Biotechnology to (thousands of euros): in Spain;Total 2021;123.416
Purchase of services R & D in Biotechnology to (thousands of euros): in Spain;Companies;95.870
Purchase of services R & D in Biotechnology to (thousands of euros): in Spain;P.A.;21.807
Purchase of services R & D in Biotechnology to (thousands of euros): in Spain;Higher Education;3.035
Purchase of services R & D in Biotechnology to (thousands of euros): in Spain;PNPI;2.704
Purchase of services R & D in Biotechnology to (thousands of euros): Abroad;Total 2021;51.401
Purchase of services R & D in Biotechnology to (thousands of euros): Abroad;Companies;49.570
Purchase of services R & D in Biotechnology to (thousands of euros): Abroad;P.A.;1.654
Purchase of services R & D in Biotechnology to (thousands of euros): Abroad;Higher Education;23
Purchase of services R & D in Biotechnology to (thousands of euros): Abroad;PNPI;154
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total 2021;42,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Companies;39,8
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;P.A.;63,3
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Higher Education;57,6
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;PNPI;61,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total 2021;11,9
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Companies;12,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;P.A.;6,7
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Higher Education;9,1
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;PNPI;15,4
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total 2021;21,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Companies;18,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;P.A.;45
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Higher Education;40,9
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;PNPI;23,1
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total 2021;13,3
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Companies;11,2
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;P.A.;26,7
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Higher Education;33,3
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;PNPI;7,7
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total 2021;17,8
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Companies;15,6
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;P.A.;30
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Higher Education;42,4
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;PNPI;15,4
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and marketing channels;Total 2021;18,5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and marketing channels;Companies;16,5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and marketing channels;P.A.;27,5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and marketing channels;Higher Education;39,4
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and marketing channels;PNPI;30,8
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total 2021;15,6
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Companies;16,1
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;P.A.;10
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Higher Education;12,1
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;PNPI;30,8
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total 2021;40,1
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Companies;40
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;P.A.;40
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Higher Education;37,9
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;PNPI;61,5
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total 2021;54,4
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Companies;53,9
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;P.A.;58,3
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Higher Education;57,6
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;PNPI;61,5
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total 2021;21,5
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Companies;21,5
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;P.A.;24,2
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Higher Education;18,2
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;PNPI;23,1